Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reissued by stock analysts at Wedbush in a report released on Tuesday, Benzinga reports. They currently have a $29.00 target price on the stock. Wedbush’s price target suggests a potential upside of 31.70% from the company’s current price.

A number of other research analysts have also weighed in on the stock. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Canaccord Genuity Group raised their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Wolfe Research initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Intellia Therapeutics Stock Up 0.9 %

Shares of NASDAQ:NTLA traded up $0.19 during trading on Tuesday, reaching $22.02. 343,709 shares of the company’s stock traded hands, compared to its average volume of 1,496,162. Intellia Therapeutics has a fifty-two week low of $20.78 and a fifty-two week high of $47.48. The firm has a market cap of $2.12 billion, a PE ratio of -4.07 and a beta of 1.77. The company has a 50-day simple moving average of $27.05 and a 200-day simple moving average of $27.78.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The firm had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same period last year, the company posted ($1.40) EPS. On average, equities research analysts forecast that Intellia Therapeutics will post -5.58 EPS for the current year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares in the company, valued at $2,691,027.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the business. Barclays PLC grew its stake in shares of Intellia Therapeutics by 15.0% in the third quarter. Barclays PLC now owns 256,626 shares of the company’s stock worth $8,115,000 after acquiring an additional 33,558 shares in the last quarter. ARK Investment Management LLC lifted its position in shares of Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after purchasing an additional 1,463,820 shares during the last quarter. American Century Companies Inc. lifted its position in Intellia Therapeutics by 5.9% in the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock valued at $8,449,000 after acquiring an additional 14,863 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock valued at $1,104,000 after acquiring an additional 4,255 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock valued at $83,856,000 after acquiring an additional 36,630 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.